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ABSTRACT 
 
 
 
The aim of the present investigation is to purify, characterize, and determine the 
chemical and biological properties of Porphyromonas gingivalis free 
dihydroceramides (fDHC). Effects were tested by examination of human gingival 
fibroblast morphologic changes in addition to their synthesis of prostaglandin E2 
(PGE2) and prostaglandin F2α (PGF2α) produced in vitro.  Free dihydroceramides as 
well as phosphoglycerol dihydroceramide (PGDHC), and de-esterified 
phosphoglycerol dihydroceramide (PGDHC-C15:0) were obtained by total lipid 
extraction of P. gingivalis followed by high performance liquid chromatography 
(HPLC).  Confirmation and structural analysis was obtained by electrospray mass 
spectrometry (ES-/+MS) and nuclear magnetic resonance spectroscopy (NMR).  A 
synthetic free dihydroceramide (A) was obtained, and its purification and structural 
analysis was similar.  Ethanol solvent served as a negative control, and PGDHC 
served as a positive control. HGF were obtained from tissue samples of two 
periodontally healthy volunteers during clinical crown lengthening procedures, and 
cell cultures were introduced to 35 mm wells previously coated with ethanol or 20µg 
of each lipid/well.  Additional experimentation was carried out to investigate 
fibroblast response to different concentrations of P. gingivalis fDHC.  These 
experiments were carried out in a similar manner except P. gingivalis fDHC were 
studied at 0.2, 2, and 20 µg/35 mm well.  After one hour, 30 ng of interleukin-1β (IL-
1β) was added to each sample.  After 24 hours, supernatants were harvested and 100 
ng of both deuterated prostaglandin E2 (DPGE2) and prostaglandin F2α (DPGF2α) 
 vii 
were added.  Analyses were performed by derivatization of samples followed by gas 
chromatograph mass spectrometry (GC-MS).  HGF synthesis of PGF2α was 
unaffected for all lipids tested. IL-1β mediated HGF synthesis of PGE2 was greater 
for all treatment groups compared to control; however, statistical significance was 
only achieved for PGDHC and P. gingivalis fDHC (p < .05).  P. gingivalis PGDHC 
and fDHC treated HGF resulted in similar PGE2 synthesis approximately 1.8 fold 
compared to ethanol vehicle.  Morphologic changes suggestive of HGF atrophy and 
apoptosis were evident only for PGDHC, and this was noted for the majority of 
PGDHC experiments. These findings suggest that IL-1β mediated HGF secretion of 
PGE2 can occur even in the absence of a phosphate linkage and 15-carbon 
isobranched methyl ester, but these structural elements seem to play an important role 
in the induction of cellular morphological changes observed in phase contrast 
microscopy.   
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INTRODUCTION 
 
Periodontal diseases include both gingivitis and periodontitis, which affect the 
periodontal supporting tissues of teeth [1].  However, unlike gingivitis, periodontitis is 
accompanied by apical migration of junctional epithelium, destruction of connective 
tissue attachment, and alveolar bone loss [2, 3].   Approximately 30% of the adult U.S. 
population has moderate periodontitis, with 5% of the adult population experiencing 
severe periodontitis [4].  In addition, longer average lifespan has resulted in a 32-fold 
increase in the number of older dentate individuals at risk of developing periodontitis.  
More recently, epidemiological studies have shown that periodontal disease may be a 
significant etiology of various systemic diseases including coronary heart disease, 
diabetes, and COPD [5].  
Periodontal diseases are typically infectious by nature and are a consequence of 
biofilm formation[6-8].  Supragingival biofilm is predominantly composed of Gram-
positive aerobic microorganisms and creates and ecological niche enabling Gram 
negative anaerobic flora to thrive [9].  Specific bacteria cultured from periodontal pockets 
that have been described as more pathogenic than others include Aggregatibacter 
actinomycetemcomitans, Prevotella intermedia, Tannerella forsythia, Porphyromonas 
gingivalis, and Treponema denticola where the latter three have been categorized in the 
red complex of bacteria by Socransky and coworkers [10, 11].  Persistence of these 
microbes after periodontal therapy has been associated with negative outcomes [12].   
Previous investigation has shown that P. gingivalis, a Gram-negative, 
asaccharolytic, obligate anaerobic rod, is strongly associated with chronic periodontitis 
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[13].  P. gingivalis produces a broad array of potential virulence factors involved in tissue 
colonization and destruction as well as in host defense perturbation [14]. Among these 
virulence factors, trypsin-like proteinases, called gingipains, have been purified and 
characterized, and their functions and pathological roles in periodontitis have been 
extensively investigated over the past decade [15]. Gingipains are responsible for most of 
the extracellular and cell-bound proteolytic activities produced by P. gingivalis. P. 
gingivalis is in close contact with the epithelium in periodontal pockets in vivo [16] and 
can invade various cell lines, including epithelial cells [17], endothelial cells [18], and 
fibroblasts in vitro [19].  
The gingival epithelium is a stratified squamous epithelium that is an interface 
between the external environment, which is exposed to bacterial challenges, and the 
underlying periodontal tissue. The basal layer of the gingival epithelium is separated 
from and attached to the connective tissue by the basal lamina. The gingival epithelium 
can be divided into oral, sulcular, and junctional epithelia, based on their architecture. 
The sulcular epithelium, which extends from the oral epithelium to the gingival sulcus 
facing the teeth, and the junctional epithelium, which mediates the attachment of teeth to 
gingiva, are not keratinized, in contrast to the oral gingival epithelium [20]. The sulcular 
and the coronal margins of the junctional epithelium are in close contact with bacteria in 
the gingival sulcus and appear to be crucial sites with regard to the development of 
periodontal diseases. During periodontitis, loss of connective tissue attachment and bone 
resorption associated with the formation of periodontal pockets is related to the 
pathologic conversion of the junctional and the sulcular epithelium to a pocket 
epithelium. Invasion of mammalian epithelial cells is an important strategy developed by 
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pathogenic bacteria to evade the host immune system and cause tissue damage. Gingival 
epithelial cells are the primary physical barrier to infections by periodontal pathogens in 
vivo. While the epithelium was previously thought to be passive, Dale (2002) [21] 
proposed a new perspective, assigning an active role to the epithelium in the host 
response to bacterial infections. The epithelium reacts to bacterial challenges by signaling 
host responses and integrating innate and acquired immune responses. This review 
focuses on the current understanding of host epithelial cells and P. gingivalis interactions 
in the pathogenesis of periodontitis.  By contrast, periodontally healthy patients will 
have either no detectable levels of P. gingivalis or only small quantities in subgingival 
plaque samples [20].  High levels of P. gingivalis have been well correlated with severe 
loss of connective tissue attachment, deep periodontal pockets, loss of alveolar bone, and 
rapidly progressing periodontal disease [13, 22, 23].  The presence of 
periodontopathogenic microorganisms is associated with an increase in inflammatory cell 
infiltrate and cytokine production including interleukin-1β (IL-1β), interleukin-6 (IL-6), 
interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), prostaglandin E2 (PGE2
Subgingival microflora, in general, elicit a complex host immune response 
through virulence factors such as endotoxin, proteases, and lipopolysaccharide (LPS).  
LPS is a cell wall constituent of Gram-negative microorganisms.  The LPS molecule 
contains three structural components: O-specific polysaccharide, core polysaccharide, 
and lipid A.  The lipid A portion of the molecule has been shown to be responsible for the 
associated biological activity including inflammatory cell activation and inflammatory 
), as well 
matrix metalloproteinases (MMPs), which recruit lymphocytes, fibroblasts, and 
osteoclasts that damage the surrounding periodontal tissues [24].      
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cytokine production, and its potency differs among different bacterial species [25].   
Covalently linked to lipid A by either amide or ester linkages are even carbon-chain 2-
hydroxy and odd-chain isobranched 3-hydroxy fatty acids.  Bacterial LPS acts by 
associating with LPS-binding protein (LBP), and the LPS-LBP complex then binds to 
Toll-like receptor-4 (TLR-4) resulting in downstream intracellular signal transduction 
with activation of nuclear factor-kappa B (NF-κB) and eventual production of 
proinflammatory cytokines[26, 27].  Toll-like receptors are among a number of pattern 
recognition surface receptors that appear to play a role in pathogen recognition and 
initiation of inflammatory and immune responses.  Several TLR isoforms exists, and each 
one has high specificity for binding a certain pathogen-associated molecular pattern 
(PAMP) [28].  Evidence has demonstrated that “atypical” P. gingivalis LPS, 
peptidoglycan, and lipoprotein binds TLR-2 receptors [29, 30], and TLR4 appears to be 
specific for LPS [30].  
Bacterial complex lipids recovered in diseased gingival tissues include a class of 
sphingolipids, called dihydroceramides, and are produced by P. gingivalis [31].  A 
ceramide is a lipid molecule composed of a sphingosine and a fatty acid. Ceramides are 
found in high concentrations within the mammalian cell membrane phospholipid bilayer.  
Ceramides have also been key players in cellular response to stress and apoptosis [32]. 
Hydrolysis of sphingomyelin by acid sphingomyelinase results in the release of ceramide, 
while synthesis of ceramide is catalyzed by the serine-palmitoyl-CoA transferase and 
ceramide-synthase [33]. Sphingomyelin is a type of sphingolipid found in mammalian 
cell membranes most significantly in the myelin sheath around certain nerve cell axons.  
It usually consists of phosphorylcholine and ceramide.  Sphingomyelin is an important 
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facilitator of signal transduction.  Sphingolipids are derived from the aliphatic amino 
alcohol sphingosine and play an important role in both signal transmission and cell 
recognition. Ceramide molecules reorganize the cell membrane leading to the formation 
of large, distinct ceramide-enriched membrane domains, termed rafts, that serve to cluster 
and aggregate activated receptor molecules [34]. Besides the important role of ceramide 
in receptor-induced cell death, several studies demonstrate a central role of ceramide in 
UV-light, irradiation and triggered cell death [35]. Several recent publications indicate 
that ceramide is also present in mitochondria, and that mitochondrial ceramide may play 
a role in apoptosis. Mitochondrial ceramide seems to be generated through the activity of 
the acid sphingomyelinase, which has been shown to reside in the space between the 
inner and outer mitochondrial membrane [36]. Although many studies indicate a central 
role of ceramide for the induction of apoptosis after an acute stimulus, only a few data 
exist that demonstrate a contribution of ceramide to a dysregulation of apoptosis in 
human disorders. Diseases that have been shown to be caused by dysregulation of cellular 
ceramide include neurological syndromes, including hereditary sensoric neuropathy Type 
I and II. Hereditary sensoric neuropathy Type I is caused by a mutation of serine–
palmitoyltransferase 1 and an increased cellular ceramide concentration, which seems to 
be causally linked to degeneration of peripheral sensory neurons [37, 38]. Cellular 
ceramide levels are also increased in the Batten’s syndrome, which is caused by a 
mutation of palmitoyl-thioesterase and of CLN3 resulting in neuronal cell death with 
cognitive and motor decline, seizures and blindness [39]. Finally, experiments on 
Drosophila also suggest an involvement of ceramide in retina degeneration, although it is 
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not known whether similar mechanisms are effective in the corresponding human disease 
[40, 41].    
Ceramides have been linked to periodontal pathogenesis since they are readily 
recovered from disease gingival tissues and root surfaces of hopeless teeth extracted due 
to severe periodontitis [42].  More specifically, P. gingivalis, dihydroceramides have 
been detected in lipid extracts of calculus-contaminated teeth, subgingival calculus, 
subgingival plaque and in diseased gingival tissues. This evidence suggests that diseased 
gingival tissues are not simply contaminated with subgingival plaque. Regardless of the 
processes resulting in bacterial lipid accumulation in periodontitis tissue samples or 
metabolic clearance of these bacterial lipids, the recovery of phosphorylated 
dihydroceramides in diseased gingival tissues indicates that the biological properties of 
the contaminating bacterial lipids must be understood within the context of disease 
promotion [42]. 
Sharing structural similarity to lipid A, previous chemical analysis via gas 
chromatography-mass spectrometry (GC-MS) has shown that these bacterial ceramide 
lipids also contains 3-hydroxy fatty acids linked to a long chain base of either 2-amino,3-
octadecanediol or 2-amino1,3-nondecanediol amide linkage [31].  Bacterial ceramides 
share basic structural characteristics with mammalian ceramides and are therefore 
expected to promote cell activation in host cells normally susceptible to elevated levels of 
mammalian ceramides [43, 44].  P. gingivalis synthesizes free, phosphoethanolamine, 
and phosphoglycerol dihydroceramides that share a core lipid structure consisting of 
three long chain bases (17, 18, and 19 carbon aliphatic chains) in amide linkage to 3-OH 
isobranched C17:O  [45, 46].  The phosphoglycerol dihydroceramide class may be 
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substituted with isobranched C15:O linked to the beta hydroxyl of 3-OH isobranched C17:O 
[46].  These bacterial lipids are not components of lipopolysaccharide and their recovery 
in gingival tissues is not attributable to coincident bacterial invasion [31, 45].  In 
addition, mammalian cells have not been shown to produce 3-OH isobranched C17:O
For many years, periodontal therapy only aimed to remove the etiologic factors 
from the root surface and recontour hard tissue anatomical defects.  This approach 
minimizes periodontal inflammation and creates a clinical situation that is more easily 
accessible for home and professional oral hygiene practices.  With advances in tissue 
engineering and the importance of esthetics, regeneration of the periodontal attachment 
apparatus has been considered the ultimate goal of periodontal treatment.  The 
periodontium is a complex organ comprised of gingiva, periodontal ligament, alveolar 
bone, and cementum. To achieve successful periodontal regeneration, formation of an 
epithelial seal, insertion of new connective tissue fibers into the root, reformation of a 
new acellular cementum reformed on the root surface, and restoration of alveolar bone 
, and 
this fatty acid has been recovered in lipid extracts of periodontally diseased human 
cementum and gingival tissues [45].  
P. gingivalis dihydroceramides can be extracted with organic solvents directly 
from the bacterial pellet obtained after growth of the organism, centrifugation, and 
lyophillization following a protocol described by Bligh and Dyer, and Garbus et al  [47, 
48].  Following total lipid extraction, select dihydroceramides are separated by direct and 
reverse phase high performance liquid chromatography (HPLC) [46].  Confirmation of 
these fractions is possible with electrospray (ESI-MS) or gas chromatograph mass 
spectrometry (GC-MS) prior to experimentation [46].     
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are required [49]. However, the inhibition of periodontal regeneration after conventional 
treatment modalities is due to proliferation of epithelial tissues into the periodontal defect 
at a faster rate than mesenchymal tissues [50]. This leads to the formation of a long 
junctional epithelium and prevents the selective migration, proliferation, and 
differentiation of cells derived from the periodontal ligament (PDL) [51]. The concept 
that only PDL cells have the potential to create a new connective tissue attachment has 
been confirmed through investigation giving the basis for the clinical application of 
guided tissue regeneration (GTR) [52]. However, the results obtained using the GTR 
technique are reported to be unpredictable and of small magnitude [53, 54] possibly 
because of postoperative infections and the inability to completely seal the healing area 
[55]. Three basic components must be considered in periodontal tissue engineering: 1) 
appropriate signals, 2) scaffolds/barriers to enable coronal population of the appropriate 
cells from the PDL, and 3) cells from the PDL with regenerative potential. It has been 
shown that PDL cells may prevent ankylosis and root resorption in addition to 
regeneration of a new periodontal ligament with insertion into both tooth and bone. Also, 
roots covered with osteoprogenitor cells induce cementum-like tissue formation 
suggesting that cementoblast and osteoblast precursors commonly originate from the 
alveolar bone [56, 57]. The formation of new bone and cementum varies from complete 
absence to a thin layer of newly formed cementum with complete new bone formation 
covering the entire previously denuded root surface. Moreover, it may be speculated that 
differentiation of PDL cells is highly sensitive to differences in their microenvironments, 
resulting in different types of periodontal healing.  It has been shown that, [58] after 
transplantation, the number of cells increases over time and reflects sustained 
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proliferation.  These newly transplanted cells migrate to the bone surface and express 
osteoblast markers, for example osteopontin and bone sialoprotein, to facilitate 
osteogenesis; cells that migrate to PDL express the same phenotypic markers as other 
PDL cells. This confirms the hypothesis that, under some circumstances, PDL cells can 
promote periodontal regeneration.    
Independent of the periodontal disease status, the predominant cell type recovered 
in gingival connective tissue is the fibroblast [59].  Fibroblasts play an important role in 
the remodeling of extracellular matrix (ECM) by synthesizing connective tissue 
components predominantly constituted of fibrillar collagens [60].  Fibroblasts respond to 
various inflammatory cytokines and growth factors [61], and control the balance between 
ECM synthesis and degradation [62].  A shift in this normal homeostasis can lead to 
direct destruction of the periodontal connective tissue attachment apparatus and indirect 
destruction of alveolar bone through increased synthesis and secretion of 
proinflammatory cytokines (PGE2, IL-1β, IL-6, IL-8, and TNF-α) [63].  Gingival 
fibroblasts exposure to bacterial lipids is expected given the impressive recovery of 
bacterial lipids in diseased periodontal tissues [45, 64].  Fibroblasts are capable of 
secreting high levels of prostaglandin E2 (PGE2
Previous investigation has described methods regarding human gingival fibroblast 
culture from gingival tissues harvested during periodontal surgery [65].  Once cultures 
have been obtained, one can apply fibroblasts to wells contaminated with 
dihydroceramides, introduce IL-1β, and measure response via prostanoid quantification 
) [65], a proinflammatory host factor with 
ability to have adverse effects on bone and connective tissue homeostasis.  
 10 
[46].  Methods of separation, derivatization, and chemical analysis of prostanoids have 
also been previously described [66-68].      
Prostaglandins are a subclass of eicosanoids, derived from arachidonic acid, and 
are important mediators of inflammation. Prostaglandin production, more specifically 
PGE2, has been strongly associated with periodontal pathogenesis [69].   Most notably, of 
their many functions, prostaglandins are potent vasodilators and inducers of cytokine 
production by various cells.  In conjunction with proinflammatory cytokines, PGE2 acts 
on fibroblasts and osteoclasts, to induce MMP production, which is also a major 
component to the destructive process of periodontitis [69].  As demonstrated in a murine 
model, PGE2 also appears to significantly facilitate osteoclastogenesis by enhancing 
RANKL (receptor activator of nuclear factor-kappa B ligand) and depression of 
osteoprotegerin (RANKL inhibitor) [70].  Therefore, PGE2 association with destruction 
of connective tissue attachment and alveolar bone supports its central importance in the 
periodontal disease process.  Previous investigation has associated PGE2
Phosphoglycerol dihydroceramides cause the most significant morphologic changes in 
gingival fibroblasts suggesting either apoptosis and/or cell necrosis.  This line of 
evidence demonstrates the biological activity of these lipids and supports their inclusion 
among several microbial virulence factors of P. gingivalis [46].  Interestingly, short chain 
 with 
periodontitis and suggests that its concentration in gingival crevicular fluid increases in 
gingivitis relative to health and is at very high concentration during periods of 
periodontal disease progression [71]. 
Previous investigation has shown prostaglandin hypersecretory response of 
gingival fibroblasts to both phosphorylated dihydroceramide classes in vitro [46].   
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ceramides have been shown to promote interleukin-1-mediated prostaglandin E2 
secretion from dermal fibroblasts [72], and COX-1 in fibroblasts [73]. However, specific 
structure-function relationships of P. gingivalis dihydroceramides have yet to be 
determined. 
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OBJECTIVE 
 
The aim of this investigation was to isolate P. gingivalis phosphoglycerol 
dihydroceramides (PGDHC), unsubstituted PGDHC (PGDHC-C15:0), free DHC (fDHC), 
synthetic fDHC (A) and dephosphorylated PGDHC, and correlate structure with 
biological activity based on human gingival fibroblast (HGF) prostaglandin secretory 
response in vitro.  
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MATERIALS AND METHODS 
 
Previously, P. gingivalis (ATCC 33277, type strain) was inoculated into cooked meat 
medium supplemented with trypticase, yeast extract, menadione, and hemin (BBL, 
#295982, Becton Dickinson, Franklin Lakes, NJ). Once growth was established, the 
initial culture was inoculated into enriched thioglycollate medium (BBL) and prereduced 
blood agar plates. Batch suspension cultures were established after verification of 
anaerobic growth of Gram-negative rods in thioglycollate medium and demonstration of 
black-pigmented bacterial colonies on blood agar plates under anaerobic culture 
conditions. Batch suspension cultures were grown in basal [peptone, trypticase, and yeast 
extract, (BBL)] medium supplemented with hemin and menadione (Sigma; St. Louis, 
MO) and brain heart infusion. The suspension cultures were incubated in an anaerobic 
chamber flushed with N
Lipid extraction from P. gingivalis 
 
2 (80%), CO2 (10%), and H2 (10%) at 37°C for five days, and the 
bacteria were harvested by centrifugation (3,000 g for 20 min). Following lyophilization, 
~4 g of P. gingivalis pellet was extracted overnight using a modification of the 
phospholipid extraction procedures of Bligh and Dyer [47] and Garbus et al. [48]. 
Specifically, 4 ml of H20 + 16 ml of MeOH-CHCl3 (2:1; v/v) was added to the bacterial 
sample and vortexed. After 12 h, 3 ml of 2 N KCl + 0.5 M K2HPO4 and 3 ml CHCl3 
were added and the sample vortexed. The lower organic phase was carefully removed and 
CHCl3 (3 ml) was added to each sample and vortexed. The CHCl3 phase was removed 
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and combined with the previous organic solvent extract. The lipid extract from P. 
gingivalis was dried under nitrogen and stored frozen.  This sample of frozen P. 
gingivalis lipid extract was donated as a kind gift from Dr. Frank Nichols.  
 
Direct phase HPLC (d-HPLC) [1 x 25 cm silica gel, 5 µm; Supelco, Inc., Bellefonte, PA] 
was used for initial separation of bacterial lipids as well as repurification using hexane-
isopropanol-water (6:8:0.75; v/v/v: solvent A) with isocratic elution [74].  Reverse phase 
HPLC (r-HPLC) [250/4mm diatomaceous earth, 5 µm; Phenomenex] was used for 
further purification of fDHC using propanol:acetontrile (2:3; v/v: solvent B) with 
isocratic elution as well. In preparation for d-HPLC, lipid samples were dissolved in 
solvent A to achieve a concentration of ~80 mg/ml. For each chromatographic separation, 
~3 mg of lipid was applied and fractions were pooled for 25 column fractionations. 
Samples were eluted at 2.0 ml/min with 1 min fractions collected.  For r-HPLC, lipid 
samples were dissolved in solvent B.  For each chromatographic separation, ~1 mg of 
lipid was applied and fractions 1-25 were collected. During fractionation, lipid samples 
were continuously monitored at 205 nm with a UV-vis spectrophotometer. Fractions were 
dried under nitrogen and stored at resuspended in 2 ml of solvent A.  
 
 
 
 
Lipid fractionation by HPLC 
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Electrospray mass spectral analysis 
 
An additional 10 µl from each fraction was analyzed for dihydroceramide constituents 
using electrospray-MS (ESI-MS). Electrospray mass spectrometry analysis was 
accomplished using a Micromass Quattro II mass spectrometer system. Dihydroceramide 
lipid fractions, dissolved in solvent A, were injected at a maximum concentration of 100 
µg/ml. Lipid samples (10 µl) were infused at a flow rate of 20 µl/min. For electrospray 
positive-ion analyses, the desolvation and inlet block temperatures were 100°C and 
150°C, respectively, and the transcapillary potential was 3,500 volts. For electrospray 
negative-ion analyses, the desolvation and inlet block temperatures were 80°C and 
100°C, respectively, and the transcapillary potential was 3,000 volts. The cone voltage 
was usually 30 volts, and the mass acquisition range was 0–2,000 amu for initial 
electrospray MS analyses.  Fractions containing specific dihydroceramide lipids were 
pooled and repurified using the same column and elution conditions. The repurified lipids 
were evaluated for dihydroceramide recovery using ESI-MS.  A purified, synthetic fDHC 
(A) was obtained from the University of Connecticut Storrs Department of Chemistry to 
include in this investigation. 
 
Lipid recovery in each HPLC fraction was determined by drying 5 µl from each fraction 
onto a microbalance tray and weighing the tray using a Cahn Electrobalance (Ventron 
Preparation of test samples 
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Corporation, Cerritos, CA). Predetermined amounts of PGDHC, PGDHC-C15:0, A, and 
fDHC were transferred in CHCl3 to conical vials and dried. These selected HPLC 
fractions were then dissolved in ethanol to achieve a final concentration of 0.25 µg/µl, 
and 80 µl of each lipid fraction was deposited in 35 mm culture wells while the culture 
dishes were maintained in a laminar flow hood. The ethanol was allowed to evaporate 
overnight, leaving a lipid residue covering most of the culture well surface. Vehicle 
control wells received only ethanol solvent. Lipids were deposited onto culture dishes in 
this manner so that cells could be exposed to bacterial lipid fractions without introducing 
organic solvent into the culture medium.  In a second series of experiments, fDHC was 
diluted to 0.0025 µg/µl, 0.025 µg/µl and 0.25 µg/µl, and 80 µl were deposited into each 
respective 35 mm well for dose response comparison.  PGDHC, PGDHC-C15:O, and A 
were also examined in this second series of experiments.    
 
Primary cultures of gingival fibroblasts were obtained using gingival tissue, harvested at 
the time of periodontal surgery, from two separate patients and processed as previously 
described [65]. Gingival tissue samples were obtained according to a protocol approved 
by the University of Connecticut Health Center Institutional Review Board, and 
participants provided written informed consent. Primary cultures of gingival fibroblasts 
were grown in Minimal Essential Medium (MEM) supplemented with 10% fetal calf 
serum, penicillin G (100 U/ml), streptomycin (100 µg/ml), and amphotericin B (0.25 
µg/ml) (Sigma), and cells were passaged fewer than 10 times for these experiments. The 
Determination of biological activity with human gingival fibroblasts 
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cells were harvested using trypsin (0.1%, w/v) in Ca2+-, Mg2+-free phosphate-buffered 
saline and resuspended in MEM to achieve a 1:3 dilution of cells for passaging. Cells 
were cultured in an H2O-saturated, 5% CO2 atmosphere at 37°C. Fibroblasts were 
introduced to bacterial lipids by inoculation into culture wells to achieve a cell 
number/surface area equivalent to confluent cultures. After 1 h of exposure to bacterial 
lipids, 30 µl of culture medium containing human recombinant IL-1ß (final 
concentration,10 ng/ml) (Immunex; Seattle, WA) was injected to each sample. After the 
cultures were incubated for an additional 24 h, they were photographed at x100 
magnification using an Olympus phase contrast light microscope. Photomicrographs of 
the effects of P. gingivalis total lipid sample were included from a pilot experiment. 
However, quantification of total lipid induced prostaglandin production was not included 
in this experiment. Medium samples were then harvested and frozen. 
 
Prostaglandin E
Quantification of prostaglandin production by GC-MS 
 
2 (PGE2), and prostaglandin F2α (PGF2α) were quantified in medium 
samples using a modification of the method of Luderer et al. [66], previously described 
by Nichols [67]. Each medium sample was supplemented with 100 ng of D4- PGF2α and 
D4-PGE2. The fibroblast medium samples were thawed and the pH adjusted to pH 3.5 
with concentrated formic acid. The acidified medium samples were then applied to 
reverse-phase preparative columns [Supelclean, LC-18 SPE tubes, 6 ml; Supelco, Inc.] 
mounted on a vacuum manifold. Before applying the medium samples, the C-18 columns 
(3 ml) were regenerated by running sequentially 3 ml of 100% methanol followed by 3 
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ml of Ca2+-Mg2
Derivatized products of hydroxy fatty acids, long-chain bases, and prostaglandins were 
transferred to vials used for GC-MS automated sampling (crimp cap vials, 200 µl). GC-
MS was carried out on a Hewlett Packard (Avondale, PA) 5890-gas chromatograph 
interfaced with a 5988A-mass spectrometer. Prostaglandin samples were applied to an 
SPB-1 (12 m x 0.2 mm, 0.33 µm film thickness; Supelco, Inc.) column held at 100°C. 
Prostanoid samples were analyzed using a temperature program of 5°C/min from 100°C 
to 240°C. The injector block was held at 260°C, and the transfer tube was maintained at 
280°C. Prostaglandin levels were quantified using selected ion monitoring of the 
+-free phosphate-buffered saline (pH 3.5). Each acidified medium 
sample was then applied to individual SPE columns, the columns were washed with 3 ml 
of 25% methanol in water, and enriched prostaglandins were eluted with 3 ml of 100% 
methanol. The resultant samples were then supplemented with 2 ml of 1% formic acid in 
water, and the prostaglandins were extracted with 2 ml of chloroform. The chloroform 
extracts were dried under nitrogen. 
All derivatizing agents were obtained from Pierce Chemical Corp. (Rockford, IL). 
Prostaglandin samples were derivatized using the method of Waddell, Blair, and Wellby 
[68]. Prostaglandin samples were first treated with 2% methoxylamine hydrochloride in 
pyridine (30 µl). After standing overnight at room temperature, the samples were dried 
under nitrogen, dissolved in acetonitrile (30 µl), and treated with pentafluorobenzyl 
bromide (35% v/v in acetonitrile, 10 µl) and diisopropylethylamine (10 µl). The samples 
were vortexed, incubated for 20 min at 40°C, and evaporated under nitrogen. The residue 
was then treated with bistrimethylsilyl-trifluoroacetamide (BSTFA, 50 µl) and allowed to 
stand at room temperature for 4–5 days. 
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characteristic base peak ions, and bacterial fatty acids and long-chain bases were detected 
and interpreted through analysis of characteristic spectra. 
 
NMR analysis of fDHC 
 
NMR data were collected on a Bruker (Rheinstetten, Germany) DRX-400, a Bruker 
Avance 500, and a Varian (Palo Alto, CA) INOVA 600 (operating frequencies 400.144 
MHz, 500.13 MHz, and 599.75 MHz, respectively).  For bacterial fDHC, HPLC fractions 
14 and 15 lipids dissolved in a mixture of deuterated solvents (CDCl3-CD3OD). These 
data allowed the assignment of proton resonances of the dihydroceramide base and the 
phosphate side-chain of the molecule, as well as specific components of the aliphatic 
chains. A mixture of solvents was necessary in order to prevent aggregation into micelles 
or reverse micelles, depending on the solvent.  Synthetic fDHC (A) was aliquoted, 
dissolved in a mixture of deuterated solvents (CDCl3-CD3
 Test groups were compared to ethanol vehicle and each other using analysis of 
variance (ANOVA) after calculation of test/control (T/C) ratios.  Fisher PLSD, Scheffe 
F-test and Dunnett t were used to determine significance of ANOVA at 95% confidence 
OD) and analyzed in a similar 
fashion.  This further allowed for comparison between synthetic (A) and P. gingivalis 
fDHC.   
 
Statistical Analysis 
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level.  Statistical analysis was computed using a computer software package for 
Macintosh (StatView).   
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  RESULTS 
 
 P. gingivalis bacterial complex lipid structures with corresponding mass to charge 
ratio (m/z) including PGDHC, PGDHC-C15:0, and fDHC can be seen in (Fig. 1).  Lipids 
were extracted from P. gingivalis and separated by dHPLC and rHPLC.  Several 
dihydroceramide lipid moieties can be observed in the ESI-MS spectrum for the P. 
gingivalis total lipid sample in (Fig. 2).  Samples of PGDHC were obtained by dHPLC 
separation of the total lipid extract, and purity of samples was confirmed with ESI-MS 
analysis (Fig. 3).  PGDHC-C15:0 was obtained by NaOCH3
Pure samples of fDHC were obtained using rHPLC.  A sample of a UV-vis 
spectrum for fDHC fractionation after initial rHPLC separation is shown in Fig. 5 where 
fDHC elution from column is delayed and can be observed in the later peak.  After 
collection and pooling of these corresponding fractions, rHPLC was used a second time 
(Fig. 6).  In this UV-vis spectrum, the largest signal corresponds with refined separation 
of fDHC.  These fractions containing fDHC were analyzed with ESI+MS and this mass 
spectrum can be seen in Fig. 7.  As previously described, synthetic fDHC was provided 
by the University of Connecticut Storrs Department of Chemistry.  After synthesis and 
purification, characterization was performed similarly with addition of NMR 
 treatment of an aliquoted 
sample of PGDHC, separated by dHPLC, and purity of the samples was confirmed with 
ESI-MS analysis (Fig. 4).  High purity of samples can be noted by comparison of relative 
ion abundance of m/z peaks corresponding to each separated dihydroceramide.  
Corresponding solvent ESI-/+M spectrum is located below the separated 
dihydroceramide spectrum in each figure.    
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spectroscopic analysis.  ESI+MS for synthetic dihydroceramide (A) can be seen in Fig. 8.  
NMR spectra for both fDHC and A can be observed together for comparison in Fig. 9.  
An impressive similarity is noted including the finger print region between both spectra.  
The ESI+MS and the NMR data provide strong evidence of structural similarity between 
fDHC and A.   
  Morphologic changes of human gingival fibroblasts (HGF) were evaluated after 
24 hours of exposure to lipid or ethanol vehicle in addition to 30 ng IL-1ß in 35mm wells 
with phase contrast microscopy.  Photomicrographs for HGF exposure can be observed in 
Fig. 10.   Morphologic changes could not be observed for ethanol vehicle (Panel A) 
and/or fDHC (Panel D).  However, morphologic changes appearing as severe atrophy 
and apoptosis were observed after 24 hours of exposure to 20µg of PGDHC + 30 ng IL-
1ß (Panel C) and 20µg Total Lipid extract + 30 ng IL-1ß (Panel B) in 35mm wells.   
 Treatment of HGF with P. gingivalis PGDHC, PGDHC-C15:0, and fDHC as well 
as synthetic free DHC demonstrated varying potentiation of IL-1ß mediated PGE2 
secretion for both 20µg dose and fDHC dose response of 0.2, 2.0, and 20µg when 
compared to vehicle control.  PGF2α secretion was unaffected by bacterial and synthetic 
lipids (Fig. 11).  In a separate experiment comparing the effects of PGDHC-C15:0, a trend 
suggesting stimulation of HGF PGE2 secretion was noted for all lipids, but statistical 
significance was not achieved (Fig. 12). Although trends were noted for stimulation for 
all treatment groups compared to control, statistical significance was only noted for 
PGDHC (20µg ) and fDHC (20µg ) (Fig 13).  A trend for increased PGE2 secretion with 
increasing concentration of fDHC was also noted, but did not achieve statistical 
 23 
significance (Fig. 14).  The effects of all samples on HGF PGE2 and PGF2α  secretion 
was determined by calculating treatment/control (T/C) for Figures 12-14.        
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DISCUSSION 
 
 This present investigation demonstrates that, in vitro, P. gingivalis PGDHC, 
PGDHC-C15:0, fDHC, and synthetic fDHC differentially induce IL-1β mediated HGF 
secretion of PGE2.  HGF secretion of PGF2α  was unaffected by P. gingivalis and 
synthetic dihydroceramides.  PGDHC and fDHC treated HGF resulted in similar PGE2 
synthesis approximately 1.8 fold compared to ethanol vehicle (p < .05). 
 Several proinflammatory cytokines including IL-1β [75], tumor necrosis factor α 
[76], epidermal growth factor [77], and transforming growth factor β [78] are known to 
stimulate PGE2 production. Prostaglandin synthesis is regulated by the activity of both 
phospholipase A2 and cyclooxygenase (COX) [79]. Previous investigation has elucidated 
that the rate-limiting step to prostaglandin synthesis is related to COX stability since it is 
rapidly degraded and has a short half-life [80]. Adding to the complexity of this 
mechanism, IL-1 induced COX synthesis is mediated by protein-dependent post-
transcriptional events [81, 82]. Progressively, in vitro, examination of human dermal 
fibroblast IL-1-mediated PGE2 secretion has determined that spingosine and C2-
ceramide treatment resulted in an 8-fold induction of COX mRNA within 1-2 hours.  
Although lacking a phosphate head group and isobranched fatty acid linkage, C2 
ceramide has a structure relatively similar to P. gingivalis dihydroceramides.  Given these 
findings, as found for human dermal fibroblasts, a similar mechanism is expected where 
P. gingivalis and synthetic lipid samples tested in this study may increase COX 
expression accounting for the observed enhancement of IL-1β mediated PGE2 
production.         
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 More specifically, increased sulcular concentration of IL-1β and PGE2 has been 
previously shown to regulate the magnitude of tissue destruction in progressive 
periodontitis [83-88].  IL-1 is a proinflammatory cytokine that has a large array of 
biological activities and directly regulates several genes expressed during inflammation 
[89].  There are two principal forms of IL-1 with agonist activity: IL-1α and IL-1β.  A 
third ligand, IL-1ra, is an antagonist that functions as a competitive inhibitor.  Two IL-1 
receptors are found on the surface of target cells: IL-1 receptor-1 and IL-1 receptor-2.  
IL-1 is produced by many cell types including monocytes/macrophages, neutrophils, 
fibroblasts (gingival and periodontal ligament), epithelial cells, endothelial cells, and 
osteoblasts [90-93], and can induce upregulation of adhesion molecules on leukocytes 
and endothelial cells, stimulate production of chemokines, increase production of 
prostaglandins, matrix metalloproteinases, and even enhance bacterial killing and 
phagocytic activity [89, 94].  There are several lines of evidence that implicate IL-1 in the 
pathogenesis of periodontal disease [95-97].  Furthermore, experimental evidence 
suggests that susceptibility to periodontal disease is influenced by genetic polymorphisms 
of the IL-1 gene [98, 99].  Interestingly, IL-1 gene polymorphisms have also been 
associated with poorer periodontal prognosis in smokers where risk of tooth loss 
increased up to 7.7 times over a 14-year periodontal maintenance period [100].  
Impressive levels of IL-1 have been recovered in gingival crevicular fluid (GCF) in 
patients with periodontal disease compared to healthy controls.  According to Salvi et al., 
GCF IL-1 levels were approximately 17 ng/ml for healthy controls, 116 ng/ml for 
gingivitis patients, 263 ng/ml for chronic periodontitis patients and as high as 458 ng/ml 
for aggressive periodontitis patients [101].  Similarly, many studies have reported that 
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GCF PGE2 levels are significantly elevated in patients with periodontal disease compared 
to healthy controls. In a monkey model, previous investigation has shown that crevicular 
fluid concentration of PGE2 may be elevated up to threefold during only two months of 
periodontitis progression [83]. In the same model, with a placebo-controlled double-
blinded study, this group has also demonstrated that local administration of a non-
steroidal anti-inflammatory agent (Ketoprofen cream) significantly reduced crevicular 
fluid PGE2 concentration with corresponding gain in alveolar bone over a 6 months 
follow up period.  Confirmed in a human model of experimental gingivitis, increased 
GCF PGE2 levels were found at 4 weeks following cessation of oral hygiene procedures 
[85].   According to Seymour et. al., GCF PGE2 levels (ng/ml) were as high 20, 50, 42, 
82, and 90 examining 21 healthy, 28 gingivitis, 21 periodontitis, 15 aggressive 
periodontitis, and 15 refractory periodontitis patients, respectively [84].  In review of 
these findings, it seems clear that IL-1 and PGE2 are highly important inflammatory 
mediators implicated in the pathogenesis of periodontitis.   
Previous literature has demonstrated that 3-OH isoC17:0 
These findings are similar to results found previously examining the effects of P. 
gingivalis total lipid extract and PGDHC on HGF cultures, in vitro [46].  However, in this 
study, less impressive recovery of PGE
is readily recovered in 
both organic and aqueous solvent extracts of plaque samples, teeth and root sections 
substantiating the presence of bacterial complex lipid and LPS levels, respectively.  This 
bacterial hydroxy fatty acid is only recovered from lipid extracts of P. gingivalis, 
Prevotella, Bacteroides, Capnocytophaga [102, 103], Flavobacterium [104, 105], and 
Myxobacteria [106], but not synthesized by mammalian tissues.         
2 was noted.  This finding may be a result of 
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response variation between subjects or associated with prolonged age of the cell cultures.  
Genetic variation of fibroblast phenotype, although not related to secretion of 
prostanoids, has been exhaustively demonstrated in association with hereditary gingival 
fibromatosis [107].  Given this information, one could conclude that it is quite possible to 
have a broad range of HGF responsiveness when exposed to P. gingivalis lipids.  
Although HGF were passaged less than ten times, this treatment occurred over a period 
of approximately eight months.  A more representative HGF synthesis of PGE2
LPS is a devastating virulence factor of P. gingivalis, Aggregatibacter 
actinomycetemcomitans, as well as other Gram-negative bacteria.  LPS acts as a microbe-
associated molecular pattern recognized through pattern-recognition receptors on resident 
immune and non-immune cells within the periodontium [108].  As a result, inflammatory 
cells are recruited, osteoclasts are activated, and prostanoids, lytic enzymes, and 
proinflammatory cytokines are secreted [109, 110].  Murine models have been used to 
demonstrate the devastating effects localized LPS injection has on the periodontium 
including severe inflammation and alveolar bone loss.  Historically, these studies isolated 
LPS from non-periopathogenic bacteria including Escherichia coli or Salmonella 
typhimurium [111-113].  However, more recently, Rogers et al. observed that local 
injection of A. actinomycetemcomitans LPS in Sprague-Dawley rats induced severe bone 
 would be 
expected with increased sample size of subjects for biopsy and decreased storage time of 
HGF clones.  In consideration of these limitations, future investigations will include 
increased numbers of subjects willing to donate biopsy samples as well as completion of 
testing within a shorter time frame.   
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loss over an 8 week period using micro-computed tomography and histologic evaluation 
[114].   
The available literature clarifies the virulence potential of both bacterial complex 
lipids and LPS to play a direct role in periodontal pathogenesis. Although both of these 
lipid groups are components of the bilayer membrane of certain bacteria involved in 
periodontal disease, controversial evidence suggests that the recovery of LPS in diseased 
gingival tissues may be less than expected.  As stated previously, long-chain 3-hydroxy 
fatty acids are covalently linked to the lipid A component of LPS as well as the long 
chain base of bacterial complex lipids of P. gingivalis, Prevotella, Bacteroides, 
Capnocytophaga [102, 103], Flavobacterium [104, 105], and Myxobacteria [106], but 
not synthesized by mammalian tissues.   After extraction procedures, Nichols (1994) 
found that LPS 3-hydroxy iC17:0 and bacterial complex lipid 3-hydroxy iC17:0 are 
recovered in the aqueous and organic phase, respectively [45].  Subsequently, both LPS 
and bacterial complex lipid distribution were determined for two periodontal pathogens 
(P. gingivalis and Prevotella intermedia), subgingival plaque samples and gingival tissue 
samples both isolated from gingivitis and severe periodontitis sites.  Mean values of 3-
hydroxy iC17:0 recovered in organic solvent extracts of P. gingivalis and P. intermedia 
strains ranged from 56-63% and only < 5% of the total 3-hydroxy iC17:0, respectively.  
Organic solvent extract of subgingival plaque samples contained 75% of the total 3-
hydroxy iC17:0 for periodontitis subjects and only 43% for gingivitis subjects.  Finally, for 
gingival tissue samples, 3-hydroxy iC17:0 was primarily recovered only in organic solvent 
extracts of both healthy and mildly inflamed and periodontitis gingival tissue samples.  In 
conclusion, these results indicate that LPS from these organisms is not present in 
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substantial levels in diseased gingival tissues.  Furthermore, the significant recovery of 3-
hydroxy iC17:0 in organic solvent from periodontitis plaque samples and gingival tissue 
suggests that bacterial complex lipid, from the aforementioned select bacterial species, 
may be responsible for a more significant fraction of the lipid component of periodontal 
pathogenesis.  
Of clinical relevance, adequate removal of lipids for experimental purposes 
requires the use of toxic organic solvents such as chloroform [42].  Since these structures 
are extremely hydrophobic, their removal during routine non-surgical and surgical 
therapy will be limited to mechanical debridement of cementum and locally inflamed soft 
tissue.  Significant amounts of lipid remaining on the root surface are expected since they 
are insoluble by aqueous irrigation, and mechanical debridement of teeth to remove 
calculus is limited even with adequate surgical access [115].  Removal of bacterial 
complex lipids in inflamed gingival tissues with resective periodontal surgery may be 
related to the observation of decreased units of gingival inflammation, evident in 6 month 
follow-up biopsy samples, compared to non-resective [116].  Furthermore, the 
persistence of lipid on the root surface may also have limiting effects on regeneration 
potential of the periodontium.  Not only were the HGF significantly reactive to the 
presence of both PGDHC and P. gingivalis fDHC, as evident by secretion of PGE2
Of the bacterial lipids and synthetic fDHC examined, HGF morphologic changes 
were only noted for PGDHC; additionally, the majority of PGDHC experiments resulted 
in appearance of cellular changes observed with phase contrast microscopy.  A potential 
, but 
the majority of photomicrographs taken of HGF exposed to PGDHC revealed cellular 
morphological changes suggestive of apoptosis.   
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explanation for this finding may be the presence of both a phosphate head group and an 
ester-linked 3-OH 15-carbon isobranched fatty acid.  This unique combination of these 
structural elements of PGDHC may be specific for the molecule’s biologic activity on 
HGF in vitro.  Interestingly, LPS lipid A contains two phosphate groups coupled to 
glucosamines, and previous investigation has shown that removal of one of these 
phosphate groups generates a monophosphoryl lipid A that is 100-fold less toxic than the 
unmodified lipid A [117].  Alkaline phosphatases have been shown to modify LPS by 
dephosphorylating its lipid A moiety [118-121].  Alkaline phosphatase is a glycoprotein 
and membrane bound enzyme that increases local concentrations of phosphate ions [122]. 
In the periodontium, alkaline phosphatase is a very important enzyme as it is part of the 
normal turnover of the periodontal ligament, root cementum formation and maintenance, 
and bone homeostasis [122].  It is produced by fibroblasts, osteoblasts, osteoclasts, as 
well as many other cells, but the primary source of alkaline phosphatase in gingival 
crevicular fluid is neutrophils [122] where it functions in superoxide generation, an 
important defense mechanism of this cell [123].  In a more recent investigation, using a 
zebrafish model, Guillemin and coworkers have demonstrated the LPS detoxifying 
effects of alkaline phosphatase [124].  No effect on survival was noted when wild-type 
animals were exposed to LPS and when animals with blocked expression of intestinal 
alkaline phosphatase were exposed to previously dephosphorylated LPS via calf intestinal 
alkaline phosphatase.  However, when animals with blocked expression of intestinal 
alkaline phosphatase were exposed to LPS, toxic effects were readily apparent with 100% 
mortality within the following 48-hour time period after administration.  These authors 
conclude that intestinal alkaline phosphatase protects these animals from the toxic effects 
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of LPS, and that “commensal” flora may actually be toxic in the absence of this adaptive 
physiology.  In this experiment, bacterial fDHC and PGDHC stimulated IL-1β HGF 
PGE2 secretion was similar despite the absence of the phosphate head group in the fDHC 
organic structure.  Aside from the minimal recovery of LPS from plaque and gingival 
tissue samples from patients with periodontitis as mentioned previously, possible 
protection of LPS toxicity by GCF alkaline phosphatase dephosphorylation warrants 
further investigation.  Future experimentation examining the effects of bacterial complex 
lipid and LPS phosphate groups may lead to a better understanding of structure function 
relationships and the role of alkaline phosphatase in periodontal disease mechanisms.   
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CONCLUSION 
 
 Further studies are needed to evaluate the structure function relationship of 
bacterial complex lipids and LPS as well as the potential protective effect of alkaline 
phosphatase in periodontal diseases.  Larger sample sizes may clarify the potential effects 
of these various structural elements as well as dose response relationships.  Other future 
investigations including effects on osseointegration, development of multiple sclerosis in 
a murine model, and the removal of lipids from contaminated root surfaces are either 
planned or currently in progress. 
 In summary, through the use of reverse and direct phase HPLC, pure samples of 
P. gingivalis PGDHC, PGDHC-C15:0, and fDHC were obtained and confirmed with ESI-
MS (ESI+MS for fDHC).  Synthetic fDHC was obtained from the University of 
Connecticut Storrs graduate chemistry department, and molecular structure was 
confirmed using ESI+MS and NMR with consistent comparison to P. gingivalis fDHC.   
In vitro, P. gingivalis PGDHC, PGDHC-C15:0, fDHC, and synthetic fDHC differentially 
induce IL1-β mediated HGF secretion of PGE2.  HGF secretion of PGF2α  was unaffected 
by P. gingivalis and synthetic dihydroceramides.   PGDHC and fDHC treated HGF 
resulted in similarly increased PGE2 synthesis approximately 1.8 fold compared to 
ethanol vehicle (p < .05).  In addition, morphologic changes suggestive of HGF atrophy 
and apoptosis were evident only for PGDHC, and this was noted for the majority of 
PGDHC experiments.           
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Figure 1.  Chemical structures of P. gingivalis complex lipids are given with 
corresponding mass to charge ratios (m/z).  PGDHC consists of a fatty acid, 3-OH 
isoC17:O, and a long chain base that varies from 17-19 carbons in length.  When PGDHC 
is treated with NaOCH3
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, resultant de-esterification yields unsubstituted PGDHC (unsub 
PGDHC) which is essentially structurally identical to PGDHC minus a 15-carbon 
isobranched methyl ester.  Both PGDHC and Unsub PGDHC contain a phosphoglycerol 
head group.  Free DHC is structurally identical to unsub PGDHC minus the 
phosphoglycerol head group.  Two other previously investigated P. gingivalis lipids, 
phosphoethanolamine and phosphatidylethanolomine, were not tested in this experiment, 
but were included in this figure for completeness. Figure was provided by Frank Nichols.    
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Figure 2. ESI – spectrum of total lipid extract of P. gingivalis. Predominant ion 
abundances (m/z: 960, 946, 932) correspond to PGDHC.  Lower spectrum corresponds to 
solvent. 
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Figure 3. ESI - spectrum of PGDHC fractions after separation of P. gingivalis total lipid 
extract with dHPLC. Purity of sample can be appreciated by comparing relative ion 
abundances between PGDHC (m/z: 960, 946, 932) seen in upper spectrum and solvent in 
lower spectrum.   
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Figure 4. ESI - spectrum of PGDHC – C15:0 fractions after separation of P. gingivalis 
total lipid extract with dHPLC.  Again, purity of sample can be determined by 
comparison of relative ion abundance between PGDHC-C15:0 and other signals including 
solvent spectrum below.  High ion abundance signal to the left in the spectrum 
corresponds to negligible fatty acid moieties.   
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Figure 5. UV-vis spectrum of rHPLC at 205 nm.  Second peak corresponds to fDHC 
determined by ESI + mass spectrometry (not shown). 
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Figure 6. UV-vis spectrum monitored at 205 nm of fDHC fraction collected from first 
separation of P. gingivalis.  Free DHC fraction corresponds with strongest peak 
determined by ESI + mass spectrometry (shown in Figure 7). 
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Figure 7. ESI + spectrum of P. gingivalis fDHC fractions after separation P. gingivalis 
total lipid extract with rHPLC. Purity of sample can be appreciated by comparing relative 
ion abundances between fDHC (m/z: 584, 570, 556) seen in upper spectrum and solvent 
in lower spectrum.   
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Figure 8. ESI + spectrum of synthetic fDHC fraction (A). Purity of sample can be 
appreciated by comparing relative ion abundances between synthetic fDHC (A) with an 
isobranched C17:0
 
 long chain base (m/z: 556) seen in upper spectrum and solvent in lower 
spectrum.   
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Figure 9. NMR spectra of P. gingivalis fDHC fractions (red and blue spectra) and 
synthetic fDHC (black spectrum).  A high degree of similarity between bacterial and 
synthetic fDHC can be appreciated.   
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Panel A    Panel B 
 
  
Panel C    Panel D 
 
 
Figure 10. Phase contrast photomicrographs at 100x magnification of HGF in 35mm 
culture wells with ethanol vehicle (Panel A), total lipid extract (Panel B), PGDHC (Panel 
C), and fDHC (Panel D) for 24 hours.  Normal HGF morphology is noted for ethanol 
vehicle and fDHC (Panels A and D).  Cellular apoptosis is noted for Total lipid extract 
and PGDHC (Panels B and C).   
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Figure 11. Comparison of HGF production of PGE2 and PGF2α .  Error bars represent 
standard deviations for each sample.   
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Figure 12. Prostaglandin release given as treatment/control (T/C) for each sample 
examined. Ethanol control is not shown.  Error bars represent standard deviations.   
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Figure 13. Prostaglandin release given as treatment/control (T/C) for each sample 
examined. Ethanol control is not shown.  Error bars represent standard deviations. 
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Figure 14. Prostaglandin release given as treatment/control (T/C) for each sample 
examined. Ethanol control is not shown.  Error bars represent standard deviations. 
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